[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626828":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Kaiser Clinic and Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 - Experimental","EXPERIMENTAL","Continuous Glucose Monitoring (iCan i3)",[13],"Device: Can i3 Continuous Glucose Monitoring System",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm 2 - Active Comparator","ACTIVE_COMPARATOR","Capillary Glucose Monitoring (fingerstick using glucometer)",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Can i3 Continuous Glucose Monitoring System","Intervention 1 - Experimental Arm Device: iCan i3 Continuous Glucose Monitoring System\n\nParticipants assigned to the experimental group will use the iCan i3 continuous glucose monitoring (CGM) system for 60 days. The sensor will be inserted in the abdominal region and will provide real-time interstitial glucose readings every 3 minutes via Bluetooth connection to a mobile application. Sensors will be replaced every 15 days, totaling four cycles during the study period. Data will be continuously recorded and stored for subsequent analysis. Participants will also record hypoglycemic symptoms and meal timing in a study diary.\n\nIntervention 2 - Active Comparator Arm Device: Capillary Glucose Monitoring (Glucometer - Sinocare)\n\nParticipants assigned to the control group will perform capillary blood glucose monitoring using a glucometer (Sinocare). Measurements will be performed up to three times per day, preferably in the presence of hypoglycemic symptoms, using fingerstick sampling with",[9,15],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Roberto Luiz Kaiser Junior, PhD","CONTACT","+ 55 17 3302-4781","kaiserjr@kaiserclinica.com.br",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Kaiser Clínica Hospital Dia","RECRUITING","São José do Rio Preto","São Paulo","15015-110","Brazil","BR",{"type":42,"coordinates":43},"Point",[44,45],-49.37944,-20.81972,{"lat":45,"lon":44},[48,49],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},{"name":50,"role":29,"phone":30,"phoneExt":25,"email":51},"Flavio Pirozzi, PhD","cepkaiser@kaiserclinica.com.br",{"type":53,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100626828","continuous-glucose-monitoring-with-ican-i3-in-post-bariatric-patients-with-late-dumping-syndrome-100626828",false,"NCT07440706","Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping Syndrome","A Prospective Randomized Study Evaluating the Efficacy and Safety of the iCan i3 Continuous Glucose Monitoring System in Post-Bariatric Patients With Late Dumping Syndrome","iCan3 Dumping","Inclusion Criteria:\n\n* Age 18-65 years\n* History of Roux-en-Y gastric bypass ≥12 months\n* Clinical diagnosis of late dumping syndrome\n* Stable body weight (\\\u003C5% variation in last 3 months)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosis of diabetes mellitus under treatment\n* Use of antidiabetic medications (except acarbose)\n* Pregnancy or breastfeeding\n* Cognitive impairment affecting study participation\n* Known hypersensitivity to CGM adhesives\n* Conditions increasing risk of hypoglycemia (e.g., prolonged fasting)\n* Active or prior malignancy\n* Need for imaging procedures during study period","ALL","18 Years","65 Years",{"count":66,"type":67},60,"ESTIMATED","INTERVENTIONAL",[70],"NA","Late dumping syndrome is a common complication following Roux-en-Y gastric bypass, characterized by postprandial hypoglycemia with significant impact on patient safety and quality of life. Traditional capillary glucose monitoring has limited ability to detect rapid glycemic fluctuations.\n\nThis prospective randomized study aims to evaluate the efficacy and safety of the iCan i3 continuous glucose monitoring (CGM) system compared to conventional capillary glucose monitoring in detecting hypoglycemic events in post-bariatric patients with late dumping syndrome.\n\nParticipants will be randomized into two groups: one using CGM and one using standard fingerstick monitoring, and followed for 60 days. Clinical outcomes, hypoglycemia frequency, symptom correlation, and quality of life will be assessed.",[73,74],"Dumping Syndrome","Post-bariatric Hypoglycemia",[76,77,78,79,80],"Late Dumping Syndrome","Post-Bariatric Hypoglycemia","Continuous Glucose Monitoring","Roux-en-Y Gastric Bypass","Hypoglycemia","2026-02-23",{"date":83,"type":84},"2026-02-27","ACTUAL",{"date":86,"type":84},"2025-10-15",{"date":88,"type":67},"2026-12-31",{"name":5,"class":6},1]